BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17060859)

  • 1. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
    Subklewe M; Marquis R; Choquet S; Leblond V; Garnier JL; Hetzer R; Swinnen LJ; Oertel S; Papp-Vary M; Gonzalez-Barca E; Hepkema BG; Schoenemann C; May J; Pezzutto A; Riess H
    Transplantation; 2006 Oct; 82(8):1093-100. PubMed ID: 17060859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
    Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
    Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients.
    Babel N; Vergopoulos A; Trappe RU; Oertel S; Hammer MH; Karaivanov S; Schneider N; Riess H; Papp-Vary M; Neuhaus R; Gondek LP; Volk HD; Reinke P
    Transplantation; 2007 Aug; 84(3):387-91. PubMed ID: 17700165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
    Johnson LR; Nalesnik MA; Swerdlow SH
    Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simian virus 40 in posttransplant lymphoproliferative disorders.
    Vilchez RA; Jauregui MP; Hsi ED; Novoa-Takara L; Chang CC
    Hum Pathol; 2006 Sep; 37(9):1130-6. PubMed ID: 16938517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases.
    Wood BL; Sabath D; Broudy VC; Raghu G
    Cancer; 1996 Nov; 78(10):2223-8. PubMed ID: 8918418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus.
    Koch DG; Christiansen L; Lazarchick J; Stuart R; Willner IR; Reuben A
    Liver Transpl; 2007 Jun; 13(6):904-12. PubMed ID: 17539010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of lymphoid neoplasia after cardiothoracic transplantation: the influence of underlying disease and human leukocyte antigen type and matching.
    Higgins CD; Swerdlow AJ; Smith JD; Hunt BJ; Thomas JA; Burke MM; Crawford DH; Yacoub MH
    Transplantation; 2003 May; 75(10):1698-703. PubMed ID: 12777859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA; Hamilton-Dutoit S
    Transplantation; 2003 Sep; 76(6):984-8. PubMed ID: 14508366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
    Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.